BOSTON, MA & CAMBRIDGE, MA – QMENTA and Amylyx Pharmaceuticals today announced a collaboration to support Amylyx’s upcoming clinical trial of AMX0035 in Alzheimer’s disease. QMENTA will use its advanced cloud-based neuroimaging platform to provide imaging data management, analysis, and visualization services for Amylyx. With QMENTA’s platform, magnetic resonance imaging (MRI) data collected as part of the clinical trial will be visualized in 3D, with advanced statistics applied to discover trends and outliers in the data.
AMX0035, designed to block pathways of nerve cell death and inflammation occurring in Alzheimer’s neurodegeneration, has previously demonstrated positive effects in cellular and animal models and is currently under clinical investigation for the treatment of amyotrophic lateral sclerosis (ALS).
The PEGASUS Trial
The PEGASUS study is a multi-center, placebo-controlled Phase 2 clinical trial designed to evaluate the safety and tolerability of AMX0035 over 6 months of treatment and to determine treatment-related effects on imaging and biochemical biomarkers. Funding support for the PEGASUS study is provided by the Alzheimer’s Combination Therapeutics Opportunity (ACTO) initiative, a collaboration between the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation. The PEGASUS study is the first trial funded through the ACTO initiative.
QMENTA will provide its cloud-based platform, data management, and aggregation services for clinicians and investigators involved in the trial. The integration of the platform will enable scientists to have a clear and safe data collection that they can analyze with QMENTA’s powerful automated analytics that will be implemented, such as cerebral blood flow or diffusion metrics in addition to sharing the data and results with their colleagues through the cloud capabilities of the platform.
”We are excited to partner with Amylyx on this study. Our aim is to accelerate and support the trial with our analytical tools. For researchers this means increasing accuracy in analyses and enabling data sharing and collaboration.Paulo RodriguesCEO at QMENTA
”Amylyx is pleased to partner with QMENTA on the PEGASUS clinical trial. We hope that this trial will provide valuable insights into AMX0035 and Alzheimer’s disease biology. This partnership reinforces the important role that innovative pharmaceutical and biomedical research providers such as QMENTA play in the drug development process. Alzheimer’s disease has a unique neuroimaging signature, and we are confident that with QMENTA’s platform and expertise we will collect accurate and consistent data to best support and understand AMX0035’s biological effects.Kent LeslieChief Scientific Officer at Amylyx
About Alzheimer’s disease
Alzheimer’s disease (AD) is a tremendous unmet medical need, affecting over five million patients in the U.S. alone. Forecasts indicate that by 2050 that number may approach 16 million people. Alzheimer’s disease is the 6th leading cause of death and represents $259 billion of direct healthcare costs in 2017, expected to reach more than $1.1 trillion in 2050.
About the partners
QMENTA offers a cloud-based platform to streamline the medical imaging workflow for running clinical trials. QMENTA’s aim is to accelerate the discovery and development of new treatments for neurological diseases using state-of-the-art image processing techniques in a seamless way. The easy-to-use features of the platform enable investigators to perform their work faster and run advanced quantification analysis on their medical images in a safe and compliant environment. The ability to easily and securely share the data from different sites ensures clinicians that the trial is running smoothly.
QMENTA has been growing since 2013 in EU & US, now supporting many multi-center studies and a number of clinical trials. The company was named “Best New Radiology Vendor” in 2017 by Aunt Minnie and was a European Winner for Accenture’s Healthtech Innovation Challenge and won the Sanofi Tech Lab challenge. Learn more at: www.qmenta.com
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company currently developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. The company’s therapeutic, AMX0035, targets the neuroinflammation and nerve cell death that characterize these diseases. AMX0035 is a proprietary combination of existing compounds that have worked synergistically to prevent cell death and neurotoxic inflammation in multiple preclinical models. Learn more about the PEGASUS study here.
AMX0035 entered a Phase 2 clinical trial (CENTAUR) in ALS patients in June 2017. Learn more at: www.amylyx.com